I decided to check endpoints of sacituzumab govitecan's trials. No mOS as an endpoint. I did see that they excluded patients with brain metastasis. I do know at least one of our patients had brain metastasis. If there were several and still managed to beat sacituzumab govitecan that would be truly remarkable.